For the second year in a row, the Children’s Tumor Foundation is among a small group of foundations invited to speak at the Biotechnology Industry Organization CEO and Investors Conference, today at the Waldorf-Astoria in New York City. The BIO conference is a forum for emerging biotechs to meet investors and form partnerships with larger pharmas; for CTF, it is a valuable opportunity to present the pipeline of candidate neurofibromatosis drugs currently in preclinical testing and clinical trials, and to engage new industry partners who have drugs that could be future neurofibromatosis treatments. CTF Chief Scientific Officer Dr. Kim Hunter-Schaedle will present at 3pm. This terrific opportunity builds on CTF’s recent invited presentation at the Milken Institute’s Partnering for Cures conference which can be viewed here.
CTF Presents Neurofibromatosis Pipeline at BIO CEO and Investors Conference
